# PQR309 in Phase 2 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma

> **NCT03120000** · PHASE2 · WITHDRAWN · sponsor: **PIQUR Therapeutics AG**

## Conditions studied

- Primary Central Nervous System Lymphoma

## Interventions

- **DRUG:** PQR309

## Key facts

- **NCT ID:** NCT03120000
- **Lead sponsor:** PIQUR Therapeutics AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-12
- **Primary completion:** 2018-12
- **Final completion:** 2019-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Withdrawn
- **Last updated:** 2018-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03120000

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03120000, "PQR309 in Phase 2 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03120000. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*